MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Kura Oncology Inc

Suletud

SektorTervishoid

6.36 -3.64

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.24

Max

6.66

Põhinäitajad

By Trading Economics

Sissetulek

-38M

-57M

Müük

-40M

14M

Kasumimarginaal

-407.067

Töötajad

192

EBITDA

-48M

-65M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+293.94% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

24M

550M

Eelmine avamishind

10

Eelmine sulgemishind

6.36

Uudiste sentiment

By Acuity

67%

33%

328 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Kura Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. juuli 2025, 21:01 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 20:46 UTC

Tulu

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. juuli 2025, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 20:36 UTC

Tulu

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. juuli 2025, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. juuli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. juuli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. juuli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. juuli 2025, 18:24 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. juuli 2025, 18:19 UTC

Tulu

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. juuli 2025, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. juuli 2025, 18:11 UTC

Tulu

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. juuli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. juuli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. juuli 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 16:04 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. juuli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. juuli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. juuli 2025, 15:47 UTC

Market Talk
Tulu

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Kura Oncology Inc Prognoos

Hinnasiht

By TipRanks

293.94% tõus

12 kuu keskmine prognoos

Keskmine 26 USD  293.94%

Kõrge 40 USD

Madal 8 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Kura Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

11

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

5.575 / 6.6Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

328 / 376 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.